Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer
Authors:
- 20 February 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 162 (1) , 17-27
Abstract
Objectives: Immune checkpoint inhibitors, a revolutionary class of cancer immunotherapy drugs, have transformed cancer treatment by bolstering antitumor immunity for various advanced-stage solid cancers. The US Food and Drug Administration has approved 7 immune checkpoint inhibitors that target 3 major immune checkpoint proteins: cytotoxic T-lymphocyte–associated protein 4, programmed cell death 1 protein, and programmed cell death 1 ligand 1. In addition to their remarkable efficacy, however, these inhibitors have been observed causing immune-related adverse events, particularly immune checkpoint inhibitor–related colitis, which often results in severe or life-threatening clinical issues. Methods: The diagnosis of immune checkpoint inhibitor–related colitis relies on incorporation of clinical evaluation as well as endoscopic and histopathologic examination, with exclusion of other potential etiologies. Results: The common histopathologic manifestations of immune checkpoint inhibitor–related colitis are acute active colitis, chronic active colitis, microscopic colitis (collagenous or lymphocytic), and ischemic colitis, with patterns overlapping. Notably, enterocyte apoptosis is a unique feature of immune checkpoint inhibitor toxicity. The proposed mechanisms for the pathogenesis of immune checkpoint inhibitor–related colitis are primarily associated with autoimmune-type dysregulation and gut microbiome alteration. This review summarizes the clinical and pathologic characteristics of immune checkpoint inhibitor–related colitis and elucidates its underlying pathogenic mechanisms. Conclusions: Future successful management of this form of colitis relies on our comprehension of the intricate interplay between tumoral and systemic immune responses to immune checkpoint inhibitors and innovative approaches to modify these responses, along with specific immune cell populations, to preclude immune-related adverse events while achieving antitumor therapeutic outcomes.Keywords
Funding Information
- Department of Pathology Internal Funding, University of Arizona College of Medicine, Tucson, Arizona
This publication has 30 references indexed in Scilit:
- Microbial mechanisms to improve immune checkpoint blockade responsivenessNeoplasia, 2022
- Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysisCancer Treatment Reviews, 2021
- Primary Human Colonic Mucosal Barrier Crosstalk with Super Oxygen-Sensitive Faecalibacterium prausnitzii in Continuous CultureMed, 2021
- Collagenous colitis and atezolizumab therapy: an atypical caseClinical Journal of Gastroenterology, 2020
- Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced GastroenterocolitisDigestive Diseases and Sciences, 2020
- Molecular Pathways of Colon Inflammation Induced by Cancer ImmunotherapyCell, 2020
- Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?British Journal of Cancer, 2020
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical PearlsCurrent Oncology Reports, 2020
- The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumabEuropean Journal of Cancer, 2017
- Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody.The Journal of Immunology, 1982